Super Lawyers
AVVO
Million Dollar Advocates Forum
Martindale-Hubbell

BioZone Pharmaceuticals Class Action

BioZone PharmaceuticalsPublicly available records indicate that a class action lawsuit has been filed on behalf of investors in Cocrystal Pharma (NASDAQ:COCP), a company formerly known as BioZone Pharmaceuticals, in connection to alleged violations of securities laws by COCP. Fitapelli Kurta is interested in speaking to investors who have complaints regarding investments made in Cocrystal Pharma between September 23, 2013 and September 7, 2018.

The class action complaint specifically alleges that during the period in question, COCP might have provided false and/or misleading material information, and/or failed to disclose adverse material information to the public, namely: the company was participating in a “pump-and-dump” scheme designed to artificially boost the price of Cocrystal’s stock; that the pump-and-dump scheme would lead to regulatory scrutiny; that the company failed to comply with the Securities and Exchange Commission’s disclosure requirements; and that consequently the company’s statements to the public during the relevant period about its business, operations and prospects were false and misleading and/or had no reasonable basis. The complaint alleges that when true facts emerged, investors suffered losses.

According to the company‚Äôs website, Cocrystal Pharma is a clinical stage biotechnology company engaged in the discovery and development of “novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.” The company uses “structure-based technologies” as well as “Noel Prize winning expertise” in its development and creation of antiviral drugs. Its current product candidates include treatments for Hepatitis C and influenza. The company’s investors include Frost Group, OPKO Health, Brace Pharma and Teva Pharmaceutical Industries, as well as two private investors. Formerly known as BioZone Pharmaceuticals, Cocrystal Pharma trades on the Nasdaq exchange under the symbol COCP.

A class action lawsuit has already been filed in connection with Cocrystal Pharma. If you wish to serve as lead plaintiff in the COCP lawsuit, you must move the Court no later than November 19, 2018. If you wish to join the litigation, please contact Marc Fitapelli at 212-658-1501 or Jonathan Kurta at 212-658-1502. There is no cost or obligation to you and your ability to share in any recovery does not require that you serve as a lead plaintiff.

Contact Information